Business Context and Reporting Period
Company: Aptevo Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2020
Event: Special Meeting of Stockholders held to vote on corporate governance proposals.
Key Financial Metrics
This filing is a current report regarding a stockholder vote and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders approved two key proposals at the Special Meeting:
- Proposal 1 (Reverse Stock Split Authorization): Approved an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-20. The specific ratio, timing, and execution remain at the sole discretion of the Board of Directors.
- Proposal 2 (Adjournment Authorization): Approved the authority to adjourn the meeting to solicit additional proxies if necessary (though no adjournment was required).
| Proposal | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| 1. Reverse Stock Split Authorization | 33,403,255 | 4,437,638 | 34,133 | None |
| 2. Adjournment Authorization | 34,007,413 | 3,786,631 | 80,982 | None |
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the stockholder vote. The primary contingency noted is the Board's discretion to determine the final reverse stock split ratio and timing.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board of Directors.
- Confirm the impact of the reverse stock split on share count and per-share ownership.
- Review subsequent filings for the actual implementation of the stock split.